» Articles » PMID: 3125168

Characterization of the Sulfonylurea Receptor on Beta Cell Membranes

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1988 Feb 25
PMID 3125168
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Specific, high affinity sulfonylurea receptors were characterized on membranes of an insulin-secreting hamster beta cell line (HIT cells). Saturable binding of the sulfonylurea, [3H]glyburide, was linear up to 0.8 mg/ml membrane protein. Scatchard analysis of equilibrium binding data at room temperature indicated the presence of a single class of saturable, high affinity binding sites with a Kd of 0.76 +/- 0.04 nM and a Bmax of 1.09 +/- 0.13 pmol/mg protein, n = 9. The insulin secretory potency of glyburide, glipizide, tolbutamide, tolazamide, and carboxytolbutamide was compared to the ability of these ligands to displace [3H]glyburide from the sulfonylurea receptor. Tolbutamide, tolazamide, and glipizide demonstrated reasonable agreement with ED50 values of 15 microM, 3 microM, and 30 nM and Ki values of 25.3 microM, 7.2 microM, and 45 nM, respectively. The inactive tolbutamide metabolite, carboxytolbutamide, at the highest concentration tested, only partially displaced [3H]glyburide from the receptor and was a very poor secretagogue. At 37 degrees C the affinity of [3H]glyburide binding, Kd = 2.0 nM, was similar to the ED50 of 5.5 nM when the free glyburide concentrations were corrected for binding of the drug to albumin. These studies suggest that sulfonylureas initiate their biologic effect through a high affinity, specific interaction with sulfonylurea receptors on the beta cell membrane.

Citing Articles

Dynamic duo: Kir6 and SUR in K channel structure and function.

Patton B, Zhu P, ElSheikh A, Driggers C, Shyng S Channels (Austin). 2024; 18(1):2327708.

PMID: 38489043 PMC: 10950283. DOI: 10.1080/19336950.2024.2327708.


Insulin Release Mechanism Modulated by Toxins Isolated from Animal Venoms: From Basic Research to Drug Development Prospects.

Sarmiento B, Menezes L, Schwartz E Molecules. 2019; 24(10).

PMID: 31091684 PMC: 6571724. DOI: 10.3390/molecules24101846.


Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis.

Rao S, Prestidge C, Miesel L, Sweeney D, Shinabarger D, Boulos R J Antibiot (Tokyo). 2016; 69(12):879-884.

PMID: 27189122 PMC: 5399159. DOI: 10.1038/ja.2016.45.


New mechanisms for sulfonylurea control of insulin secretion.

Satin L Endocrine. 2010; 4(3):191-8.

PMID: 21153274 DOI: 10.1007/BF02738684.


Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes.

Meyer M, Chudziak F, Schwanstecher C, Schwanstecher M, Panten U Br J Pharmacol. 1999; 128(1):27-34.

PMID: 10498831 PMC: 1571605. DOI: 10.1038/sj.bjp.0702763.